gdc
Ovarian Cancer

Drugs for Ovarian Cancer

Here are the financial support services available to patients receiving treatment for Ovarian Cancer.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, followed by Avastin alone, in patients with stage III or IV disease after surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after 2 or less previous chemotherapy regimens; and in combination with carboplatin and paclitaxel, or carboplatin and gemci­tabine, after Avastin alone, for patients with platinum-sensitive, recurrent disease.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Card

The program ensures a $5 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Avastin is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; and $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Doxil (doxorubicin hydrochloride liposome injection)

Drug company: Janssen
877-227-3728

Doxil is an anthracycline topoisomerase II inhibitor used for the treatment of patients with ovarian cancer.

Janssen offers 1 financial assistance program for patients using Doxil:

Johnson & Johnson Patient Assistance Foundation

This program provides Doxil free of cost to patients who meet certain financial limits and are uninsured, underinsured, or are enrolled in Medicare Part D.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used, in combination with carboplatin, for the treatment of patients with advanced ovarian cancer.

(Eli Lilly does not currently provide a specific financial assistance program for Gemzar.)

Hexalen (altretamine)

Drug company: Eisai
888-274-2378

Hexalen is an antineoplastic medication used for palliative treatment in patients with ovarian cancer.

Eisai does not currently offer financial assistance programs for Hexalen. However, Eisai has partnered with RxOutreach to provide medications at a low cost for patients with financial needs who are using Hexalen and meet the program eligibility criteria. For more information, e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. or call 800-769-3880.

Hycamtin (topotecan hydrochloride) Injection

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used for the treatment of patients with metastatic carcinoma of the ovary.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible for financial support, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Hycamtin for free until a prescription drug coverage becomes available to them.

Lynparza (olaparib)

Drug company: AstraZeneca
844-275-2360

Lynparza is a PARP inhibitor used for the maintenance treatment of patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are in a complete or a partial response to platinum-based chemotherapy, and for the treatment of patients with advanced ovarian cancer associated with deleterious or suspected deleterious germline BRCA mutation, after 3 or more chemotherapies.

AstraZeneca offers 2 financial assistance programs for patients using Lynparza:

Access 360 Lynparza Patient Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay $0 monthly for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare Limited Income Subsidy. Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Rubraca (rucaparib) Tablets

Drug company: Clovis Oncology
844-779-7707

Rubraca is a PARP inhibitor used as monotherapy for the treatment of patients with advanced ovarian cancer associated with deleterious BRCA mutation (germline and/or somatic) who received 2 or more chemotherapies, and for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients whose disease is in complete or partial response to platinum-based chemotherapy.

Clovis Oncology offers 3 financial assistance programs for patients using Rubraca:

Rubraca $0 Co-Pay Program

Patents with private insurance pay $0 copay for Rubraca through this program, with a maximum annual assistance up to $24,000.

Rubraca Connections QuickStart Program

Patients with private, commercial, or government insurance who are experiencing delays in medication coverage may be eligible to receive Rubraca at no cost for the first 15 days of treatment, up to 3 refills (maximum 60 days).

Rubraca Connections Patient Assistance Program

Patients who are uninsured or underinsured who meet certain financial and residential eligibility requirements may qualify to receive Rubraca for free.

Zejula (niraparib)

Drug company: Tesaro
844-283-7276

Zejula is a PARP inhibitor used as a maintenance treatment for adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, after complete or partial response to platinum-based chemotherapy.

Tesaro’s TOGETHER with TESARO Patient Resource Program offers 3 financial assistance programs for patients using Zejula:

Quick Start and Bridge Programs

Patients with private insurance whose prescription coverage is delayed may qualify for a 15-day supply of Zejula for free, with a maximum of 5 refills at no cost pending resolution of their coverage delay.

Commercial Co-pay Assistance Program

This program has no income requirements and can reduce the patient’s copay to $0, with an annual maximum of $26,000. The virtual copay card is initiated and utilized by a specialty pharmacy or by the healthcare provider’s office, and requires reactivation after 1 year of enrollment in the program.

Patient Assistance Program

Patients who are uninsured or underinsured who meet certain financial eligibility criteria may qualify to receive Zejula for free through this program.

Table. Drugs Prescribed for Ovarian Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab)
  • Drug company
  • Genentech
  • Indication
  • Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, followed by Avastin alone, in patients with stage III or IV disease after surgical resection

    Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after 2 or less previous chemotherapy regimens

    Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, or carboplatin and gemcitabine, after Avastin alone, for patients with platinum-sensitive, recurrent disease
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Patient Foundation
    888-941-3331


    Drug name (generic name)
  • Gemzar (gemcitabine)
  • Drug company
  • Eli Lilly
  • Indication
  • Advanced ovarian cancer, in combination with carboplatin
  • Patient support services
  • (No specific program)
    866-472-8663

    Drug name (generic name)
  • Hexalen (altretamine)
  • Drug company
  • Eisai
  • Indication
  • Ovarian cancer
  • Patient support services
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
    800-769-3880

    Drug name (generic name)
  • Hycamtin (topotecan hydrochloride injection)
  • Drug company
  • Novartis
  • Indication
  • Metastatic carcinoma of the ovary
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Lynparza (olaparib)
  • Drug company
  • AstraZeneca
  • Indication
  • Maintenance therapy in adults with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, after complete or partial response to platinum-based chemotherapy

    Adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation, after 3 or more lines of chemotherapy
  • Patient support services
  • Access 360 Lynparza Patient Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363

    Drug name (generic name)
  • Rubraca (rucaparib) Tablets
  • Drug company
  • Clovis Oncology
  • Indication
  • Advanced ovarian cancer with deleterious BRCA mutation (germline and/or somatic) after 2 or more chemotherapies

    Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients whose disease is in a complete or partial response to platinum-based chemotherapy
  • Patient support services
  • Rubraca $0 Co-Pay Program
    844-779-7707

    Rubraca Connections Patient Assistance Program
    844-779-7707

    Rubraca Connections QuickStart Program
    844-779-7707


Last modified: February 11, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country